By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Fujirebio Diagnostics, Inc. 

201 Great Valley Parkway

Malvern  Pennsylvania  19355-1307  U.S.A.
Phone: 610-240-3800 Fax: 610-240-3803


Company News
Morphotek Announces An Agreement With Fujirebio Diagnostics, Inc. To Commercialize The CA125 II Assay As A Companion Diagnostic For Farletuzumab 9/5/2017 8:18:19 AM
Fujirebio Diagnostics, Inc. CEO Paul Touhey Joins Invisible Sentine's Board of Directors 10/22/2012 9:08:37 AM
Gold Standard Diagnostics Extends Relationship with Fujirebio Diagnostics, Inc. and Signs an Exclusive US Distribution Agreement for Cyfra 21-1 EIA 10/17/2011 10:43:57 AM
FDA OKs Fujirebio Diagnostics, Inc.'s Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women Who Present with Adnexal Mass 9/6/2011 7:53:29 AM
Gold Standard Diagnostics Signs U.S. Distribution Agreement With Fujirebio Diagnostics, Inc. for Multi-Constituent Tumor Marker Control 7/13/2011 10:29:19 AM
Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 5/31/2011 9:09:07 AM
Fujirebio Diagnostics, Inc. Snaps Up Offloaded Abbott Diagnostics Unit 7/21/2010 7:07:54 AM
Becton, Dickinson and Company (BDX) and Fujirebio Diagnostics, Inc. Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 5/4/2009 6:40:55 AM
Fujirebio Diagnostics, Inc. Appoints Grady Barnes as Chief Scientific Officer 3/23/2009 10:45:14 AM
Fujirebio Diagnostics, Inc. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2/11/2009 10:56:01 AM